secwatch / observer
8-K filed March 30, 2023, 7:59 PM ET ticker HCAT CIK 0001636422
leadership confidence high sentiment neutral materiality 0.50

Health Catalyst appoints COO/CPO and new General Counsel; GC Orenstein to step down

Health Catalyst, Inc.

item 5.02item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Role change

Anne Marie Bickmore

Chief Operating Officer and Chief Product Officer
HCAT · Health Catalyst, Inc.
Effective
2023-04-03
Filed
March 30, 2023, 7:59 PM ET
On March 30, 2023, Health Catalyst, Inc. (the “ Company ”) announced that Anne Marie Bickmore, age 60, the Company’s Chief Product Officer, will assume the role of Chief Operating Officer and Chief Product Officer of the Company, effective April 3, 2023.
Departed

Daniel Orenstein

General Counsel and Corporate Secretary
HCAT · Health Catalyst, Inc.
Effective
2023-04-30
Successor
Benjamin Landry
Filed
March 30, 2023, 7:59 PM ET
On March 24, 2022, Daniel Orenstein provided notice to the Company that, effective April 30, 2023, Mr. Orenstein will step down from his position as General Counsel and Corporate Secretary of the Company to pursue other opportunities.
Appointed

Benjamin Landry

General Counsel and Corporate Secretary
HCAT · Health Catalyst, Inc.
Effective
2023-05-01
Filed
March 30, 2023, 7:59 PM ET
On March 30, 2023, the Company announced that Benjamin Landry, age 41, the Company’s Assistant General Counsel, will assume the role of General Counsel and Corporate Secretary of the Company, effective May 1, 2023.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Anne Marie Bickmore was appointed as Chief Operating Officer and Chief Product Officer at Health Catalyst, Inc..

Action
appointed
Role
Chief Operating Officer and Chief Product Officer
Exact text from the filing
On March 30, 2023, Health Catalyst, Inc. (the “ Company ”) announced that Anne Marie Bickmore, age 60, the Company’s Chief Product Officer, will assume the role of Chief Operating Officer and Chief Product Officer of the Company, effective April 3, 2023.
View on SEC.gov
Executive change SEC 8-K Item 5.02 confidence 0.95

Daniel Orenstein resigned as General Counsel and Corporate Secretary at Health Catalyst, Inc..

Action
resigned
Role
General Counsel and Corporate Secretary
Exact text from the filing
On March 24, 2022, Daniel Orenstein provided notice to the Company that, effective April 30, 2023, Mr. Orenstein will step down from his position as General Counsel and Corporate Secretary of the Company to pursue other opportunities.
View on SEC.gov
Executive change SEC 8-K Item 5.02 confidence 0.95

Benjamin Landry was appointed as General Counsel and Corporate Secretary at Health Catalyst, Inc..

Action
appointed
Role
General Counsel and Corporate Secretary
Exact text from the filing
On March 30, 2023, the Company announced that Benjamin Landry, age 41, the Company’s Assistant General Counsel, will assume the role of General Counsel and Corporate Secretary of the Company, effective May 1, 2023.
View on SEC.gov

Health Catalyst, Inc. filing history →

Source: SEC EDGAR
accession 0001636422-23-000041
view filing index on sec.gov
view primary document
Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.